Palisade Bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Palisade Bio hat ein Gesamteigenkapital von $9.9M und eine Gesamtverschuldung von $349.0K, was einen Verschuldungsgrad von 3.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $12.9M bzw. $2.9M.

Wichtige Informationen

3.5%

Verhältnis von Schulden zu Eigenkapital

US$349.00k

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$11.35m
Eigenkapital	US$9.95m
Gesamtverbindlichkeiten	US$2.92m
Gesamtvermögen	US$12.87m

Jüngste Berichte zur Finanzlage

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Mar 28

Recent updates

Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function

Jul 27

Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy

Jun 29

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Mar 28

Palisade Bio: Guarding Intestinal Integrity

Nov 07

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PALIDie kurzfristigen Aktiva des Unternehmens ($12.3M) übersteigen seine kurzfristigen Passiva ($2.8M).

Langfristige Verbindlichkeiten: PALIDie kurzfristigen Vermögenswerte des Unternehmens ($12.3M) übersteigen seine langfristigen Verbindlichkeiten ($86.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PALI über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: PALI hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: PALI hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: PALI hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 16.8% pro Jahr abnimmt

Palisade Bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Palisade Bio, Inc. announced delayed 10-Q filing

Recent updates

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

New major risk - Financial position

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Price target decreased by 33% to US$22.50

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Price target decreased by 81% to US$3.00

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

New major risk - Market cap size

Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio, Inc. Announces Board Appointments

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.220371 million.

Palisade Bio, Inc. announced that it has received funding

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery

Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer

Price target decreased to US$3.00

Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer

Palisade Bio, Inc. Announces Executive Changes

Palisade Bio, Inc. Announces Chief Executive Officer Transition

Palisade Bio announces CEO transition

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons Clinical Congress 2022

Palisade Bio, Inc. Announces the Commencement of Patient Enrollment and Dosing in Its Pivotal Phase 3 Study Evaluating LB1148

Palisade Bio streamlines operations, including cutting 20% of employees

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio GAAP EPS of -$0.12

Palisade Bio, Inc. has completed a Composite Units Offering in the amount of $12 million.

Palisade Bio, Inc. Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function

Palisade Bio Initiates Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function

Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy

Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard

Palisade Bio, Inc. announced a financing transaction

Palisade Bio, Inc. and Newsoara Biopharma Co., Ltd. Receives NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148

Price target decreased to US$4.00

High number of new directors

Palisade Bio, Inc., Annual General Meeting, Jun 09, 2022

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Palisade Bio, Inc. Appoints Robert McRae as Senior Vice President, Operations and Strategic Development

Palisade Bio to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

High number of new and inexperienced directors

Palisade Bio: Guarding Intestinal Integrity

Palisade Bio, Inc. announced that it has received $5.209141 million in funding from Yuma Regional Medical Center

Palisade Bio, Inc. announced delayed 10-Q filing

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Leading BioSciences, Inc. announced that it has received $20 million in funding from Altium Capital Management LP

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen